Bio-Rad Laboratories, Inc. Stock
Equities
BIO
US0905722072
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 296.98 USD | -2.70% |
|
-5.21% | -1.92% |
| Nov. 26 | US companies step up job cuts amid uncertain economy | RE |
| Nov. 05 | US companies step up job cuts amid uncertain economy | RE |
| Capitalization | 8.27B 7.03B 6.52B 6.09B 11.36B 760B 12.04B 74.52B 29.59B 359B 31.02B 30.38B 1,305B | P/E ratio 2025 * |
93.3x | P/E ratio 2026 * | 41x |
|---|---|---|---|---|---|
| Enterprise value | 7.88B 6.7B 6.21B 5.8B 10.82B 724B 11.46B 70.95B 28.17B 342B 29.53B 28.93B 1,243B | EV / Sales 2025 * |
3.05x | EV / Sales 2026 * | 2.93x |
| Free-Float |
64.28% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Bio-Rad Laboratories, Inc.
| 1 day | -2.68% | ||
| 1 week | -5.21% | ||
| Current month | -1.92% | ||
| 1 month | -1.28% | ||
| 3 months | -12.25% | ||
| 6 months | +15.60% | ||
| Current year | -1.92% |
| 1 week | 293.94 |  | 316.63 |
| 1 month | 293.94 | | 328.56 |
| Current year | 293.94 | | 328.56 |
| 1 year | 211.43 | | 373.69 |
| 3 years | 211.43 | | 509.62 |
| 5 years | 211.43 | | 832.7 |
| 10 years | 122.71 | | 832.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 75 | 2002-12-31 |
| President | 61 | 2024-09-08 | |
| Director of Finance/CFO | 55 | 2024-04-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeffrey Edwards
BRD | Director/Board Member | 65 | 2017-04-24 |
Gregory Hinckley
BRD | Director/Board Member | 79 | 2017-04-24 |
Norman Schwartz
CHM | Chairman | 75 | 2011-12-31 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 1.9% | 2 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.70% | -5.21% | -15.69% | -36.37% | 8.27B | |
| -0.99% | -12.02% | -13.06% | -6.03% | 189B | |
| -0.42% | +4.13% | +12.90% | +22.33% | 130B | |
| -0.15% | -0.96% | +41.75% | +117.33% | 68.56B | |
| -2.51% | -3.04% | -16.49% | -19.54% | 58.7B | |
| +1.35% | -0.66% | +18.33% | +88.44% | 53.65B | |
| -0.20% | +3.81% | - | - | 38.25B | |
| -1.74% | +4.04% | -17.50% | -32.00% | 28.83B | |
| -0.87% | -3.66% | +19.16% | +25.12% | 25.61B | |
| -1.72% | -3.42% | -0.39% | -34.77% | 23.96B | |
| Average | -1.00% | -0.86% | +3.22% | +13.83% | 62.46B | |
| Weighted average by Cap. | -0.76% | -2.98% | +3.30% | +20.45% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.58B 2.19B 2.03B 1.9B 3.54B 237B 3.75B 23.23B 9.22B 112B 9.67B 9.47B 407B | 2.64B 2.24B 2.08B 1.94B 3.62B 242B 3.84B 23.75B 9.43B 114B 9.89B 9.68B 416B |
| Net income | 91.48M 77.8M 72.12M 67.39M 126M 8.4B 133M 824M 327M 3.97B 343M 336M 14.44B | 207M 176M 163M 152M 284M 19B 301M 1.86B 740M 8.97B 775M 760M 32.63B |
| Net Debt | -396M -337M -312M -292M -544M -36.37B -576M -3.57B -1.42B -17.17B -1.48B -1.45B -62.47B | -536M -456M -423M -395M -736M -49.25B -780M -4.83B -1.92B -23.26B -2.01B -1.97B -84.59B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-23 | 297.18 $ | -2.63% | 117,086 |
| 26-01-22 | 305.22 $ | -2.03% | 301,892 |
| 26-01-21 | 311.54 $ | -0.39% | 457,475 |
| 26-01-20 | 312.76 $ | -0.25% | 130,351 |
| 26-01-16 | 313.53 $ | -2.65% | 150,274 |
Delayed Quote Nyse, January 23, 2026 at 03:10 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIO Stock
Select your edition
All financial news and data tailored to specific country editions
